Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

ABSTRACT Objective: There is a promising perspective regarding the potential effect of resveratrol in preventing and treating metabolic disturbances similar to that of calorie restriction. The aim of this study was to evaluate the effects of calorie-restricted (CR) diet on metabolic parameters and then to investigate whether resveratrol supplementation has beneficial effects similar to CR diet in patients with nonalcoholic fatty liver disease (NAFLD). Methods: This randomized controlled clinical trial was conducted in 90 patients with NAFLD (males and females) aged 20 to 60 years with body mass index (BMI) ranging from 25 to 35 kg/m2. Participants were assigned to one of three intervention groups as follows: The CR diet group (n = 30) received a prescribed low-calorie diet, the resveratrol group (n = 30) received 600 mg pure trans-resveratrol (2 × 300 mg) daily, and the placebo group (n = 30) received placebo capsules (2 × 300 mg) daily for 12 weeks. Fasting blood samples, anthropometric measurements, and dietary intake and physical activity data were collected for all participants at baseline and at the end of the trial. Results: CR diet significantly reduced weight (by 4.5%); BMI; waist circumference; waist-to-hip ratio; and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipid profiles in participants compared to resveratrol and placebo (all p < 0.05). Significant reductions in weight (by 1.1%) and BMI were found in the resveratrol group compared to the placebo group (p < 0.05). ALT, AST, and lipid profiles did not change significantly in the resveratrol group (all p > 0.05). No significant changes were seen in hepatic steatosis grade, serum glycemic parameters, and high-density lipoprotein cholesterol and sirtuin-1 levels in any group (all p > 0.05). Conclusions: CR diet with moderate weight loss has favorable effects on NAFLD, and resveratrol supplementation induced weight loss but failed to mimic other aspects of CR diet. Future studies are warranted to evaluate the long-term and dose-dependent effects of resveratrol on metabolic diseases.

[1]  Elizabeth Morris,et al.  Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease , 2019, JAMA internal medicine.

[2]  S. Asgary,et al.  Effect of resveratrol on metabolic syndrome components: A systematic review and meta-analysis , 2019, Reviews in Endocrine and Metabolic Disorders.

[3]  Andrew A. Li,et al.  Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD , 2018, Diseases.

[4]  M. F. Polat,et al.  The effect of Ramadan fasting on sirtuin and visfatin levels. , 2016, Interventional medicine & applied science.

[5]  S. Hamilton-Dutoit,et al.  Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease , 2016, Scandinavian journal of gastroenterology.

[6]  A. Lenzi,et al.  Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients , 2015, Endocrine.

[7]  A. Hekmatdoost,et al.  The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study , 2015, British Journal of Nutrition.

[8]  Yu Qin,et al.  Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[9]  K. Klein,et al.  Resveratrol does not benefit patients with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  Yu Wang Molecular Links between Caloric Restriction and Sir2/SIRT1 Activation , 2014, Diabetes & metabolism journal.

[11]  A. Hekmatdoost,et al.  Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. , 2014, Nutrition research.

[12]  H. A-Kader,et al.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. , 2014, World journal of gastroenterology.

[13]  H. Mutlu,et al.  A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. , 2014, Journal of gastrointestinal and liver diseases : JGLD.

[14]  L. Bujanda,et al.  TOPIC HIGHLIGHT , 2014 .

[15]  Yong-hui Shi,et al.  Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. , 2014, Food & function.

[16]  H. Grønbæk,et al.  Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. , 2014, World journal of hepatology.

[17]  Byung-Hoon Lee,et al.  Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase , 2014, Archives of Pharmacal Research.

[18]  A. Hekmatdoost,et al.  How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? , 2013, Hepatitis monthly.

[19]  J. Wylie-Rosett,et al.  Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD) , 2013, Nutrients.

[20]  K. Lankarani Liver Transplantation for Quality as well as Quantity of Life , 2013, Hepatitis monthly.

[21]  L. Guarente Calorie restriction and sirtuins revisited , 2013, Genes & development.

[22]  E. Ravussin,et al.  Resveratrol vs. calorie restriction: Data from rodents to humans , 2013, Experimental Gerontology.

[23]  E. Martínez-Abundis,et al.  Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. , 2013, Metabolic syndrome and related disorders.

[24]  J. Bhatt,et al.  RESVERATROL SUPPLEMENTATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE, OPEN LABEL, RANDOMIZED CONTROLLED TRIAL , 2013 .

[25]  T. Netticadan,et al.  Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients , 2013, Evidence-based complementary and alternative medicine : eCAM.

[26]  P. Schrauwen,et al.  Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? , 2013, Annals of the New York Academy of Sciences.

[27]  Nima Zamiri,et al.  Non Alcoholic Fatty Liver Disease in Southern Iran: A Population Based Study , 2013, Hepatitis monthly.

[28]  K. Schechtman,et al.  Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. , 2012, Cell metabolism.

[29]  Alexander S. Banks,et al.  Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. , 2012, Physiological reviews.

[30]  J. Bhatt,et al.  Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. , 2012, Nutrition research.

[31]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[32]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[33]  R. de Cabo,et al.  SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. , 2012, Cell metabolism.

[34]  N. Chalasani,et al.  Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease , 2012, Seminars in Liver Disease.

[35]  M. Ebrahimi-Mameghani,et al.  Lifestyle Modification through Dietary Intervention: Health Promotion of Patients with Non-Alcoholic Fatty Liver Disease. , 2011, Health promotion perspectives.

[36]  K. Lindor,et al.  Current therapies for nonalcoholic fatty liver disease. , 2011, Drugs of today.

[37]  J. Auwerx,et al.  Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. , 2011, Cell metabolism.

[38]  E. Mervaala,et al.  Distinct Effects of Calorie Restriction and Resveratrol on Diet-Induced Obesity and Fatty Liver Formation , 2011, Journal of nutrition and metabolism.

[39]  B. Sümegi,et al.  Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. , 2011, The British journal of nutrition.

[40]  T. Gotow,et al.  Closer association of mitochondria with lipid droplets in hepatocytes and activation of Kupffer cells in resveratrol-treated senescence-accelerated mice , 2011, Histochemistry and Cell Biology.

[41]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[42]  F. Milagro,et al.  Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress , 2011, British Journal of Nutrition.

[43]  Soyoung Kim,et al.  Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. , 2011, Biochemical pharmacology.

[44]  H. Lang,et al.  Weight loss increased serum adiponectin but decreased lipid levels in obese subjects whose body mass index was lower than 30 kg/m². , 2011, Nutrition research.

[45]  E. Şenateş,et al.  SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[46]  T. Szkudelski,et al.  Anti‐diabetic effects of resveratrol , 2011, Annals of the New York Academy of Sciences.

[47]  G. Kelly A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. , 2010, Alternative medicine review : a journal of clinical therapeutic.

[48]  Hongwei Yao,et al.  Regulation of SIRT1 in cellular functions: role of polyphenols. , 2010, Archives of biochemistry and biophysics.

[49]  G. Kelly A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. , 2010, Alternative medicine review : a journal of clinical therapeutic.

[50]  S. Fulda,et al.  Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. , 2010, The American journal of clinical nutrition.

[51]  J. Baur Resveratrol, sirtuins, and the promise of a DR mimetic , 2010, Mechanisms of Ageing and Development.

[52]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[53]  F. Aujard,et al.  Resveratrol activates energy metabolism by influencing body temperature, locomotor activity and resting metabolic rate in a non-human primate , 2009 .

[54]  A. Zarzuelo,et al.  Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. , 2009, Biochemical pharmacology.

[55]  Min You,et al.  Resveratrol alleviates alcoholic fatty liver in mice. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[56]  Wei-jian Jiang Sirtuins: novel targets for metabolic disease in drug development. , 2008, Biochemical and biophysical research communications.

[57]  Z. Younossi,et al.  Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis , 2008, Alimentary pharmacology & therapeutics.

[58]  D. Allison,et al.  A Low Dose of Dietary Resveratrol Partially Mimics Caloric Restriction and Retards Aging Parameters in Mice , 2008, PloS one.

[59]  Lulu Chen,et al.  Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase , 2008, Acta Pharmacologica Sinica.

[60]  C. Day,et al.  Benefits of lifestyle modification in NAFLD , 2007, Gut.

[61]  Lulu Chen,et al.  [Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats]. , 2007, Zhonghua yi xue za zhi.

[62]  M. Kaito,et al.  Restriction of dietary calories, fat and iron improves non‐alcoholic fatty liver disease , 2007, Journal of gastroenterology and hepatology.

[63]  Eric Ravussin,et al.  Calorie Restriction Increases Muscle Mitochondrial Biogenesis in Healthy Humans , 2007, PLoS medicine.

[64]  J. Auwerx,et al.  Sirtuins: The ‘magnificent seven’, function, metabolism and longevity , 2007, Annals of medicine.

[65]  P. Puigserver,et al.  Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α , 2006, Cell.

[66]  P. Puigserver,et al.  Resveratrol improves health and survival of mice on a high-calorie diet , 2006, Nature.

[67]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[68]  Jimmy D Bell,et al.  Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. , 2006, World journal of gastroenterology.

[69]  Jeanne M Clark,et al.  Weight Loss as a Treatment for Nonalcoholic Fatty Liver Disease , 2006, Journal of clinical gastroenterology.

[70]  H. Conjeevaram,et al.  One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study , 2005, The American Journal of Gastroenterology.

[71]  Myriam Gorospe,et al.  Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.

[72]  Phuong Chung,et al.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.

[73]  A. Häkkinen,et al.  Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. , 2003, Diabetes.

[74]  D. Purdie,et al.  Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C , 2002, Gut.

[75]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[76]  Kang-Yu Peng,et al.  Resveratrol exerts anti-obesity effects in high-fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3-L1 cells. , 2016, Endocrine journal.

[77]  H. Poustchi,et al.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. , 2015, World journal of hepatology.

[78]  Chwan-Li Shen,et al.  Novel insights of dietary polyphenols and obesity. , 2014, The Journal of nutritional biochemistry.

[79]  M. Tsai,et al.  Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. , 2014, Molecular nutrition & food research.

[80]  N. Møller,et al.  High-Dose Resveratrol Supplementation in Obese Men An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition , 2013 .

[81]  M. Jafarabadi,et al.  The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: Content and Construct Validity, Factor Structure, Internal Consistency and Stability , 2012 .